Flumethasone pivalate Solid powder Others Flumethasone pivalate is a synthetic glucocorticoid that is used in the treatment of various inflammatory and allergic conditions. It is a potent anti-inflammatory agent that works by inhibiting the production of inflammatory mediators. Flumethasone pivalate is available in various forms, including creams, ointments, and injections.
494.6 g/mol
$ $99 In stock
Formulation: 494.6 g/mol
Source:
Usage:
Flumethasone pivalate - 2002-29-1

Flumethasone pivalate

The product is for non-human research only. Not for therapeutic or veterinary use.

Catalog Number: BT-268299

CAS Number: 2002-29-1

Molecular Formula: C27H36F2O6

Molecular Weight: 494.6 g/mol

CAS Number 2002-29-1
Product Name Flumethasone pivalate
Molecular Formula C27H36F2O6
Molecular Weight 494.6 g/mol
Appearance Solid powder
InChI InChI=1S/C27H36F2O6/c1-14-9-16-17-11-19(28)18-10-15(30)7-8-24(18,5)26(17,29)20(31)12-25(16,6)27(14,34)21(32)13-35-22(33)23(2,3)4/h7-8,10,14,16-17,19-20,31,34H,9,11-13H2,1-6H3/t14-,16+,17?,19+,20+,24?,25?,26+,27+/m1/s1
InChI Key JWRMHDSINXPDHB-OJAGFMMFSA-N
Isomeric SMILES C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C(C)(C)C)O)C)O)F)C)F
IUPAC Name [2-[(6S,9R,11S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate
Canonical SMILES CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)COC(=O)C(C)(C)C)O)C)O)F)C)F
Description Flumethasone pivalate is a synthetic glucocorticoid that is used in the treatment of various inflammatory and allergic conditions. It is a potent anti-inflammatory agent that works by inhibiting the production of inflammatory mediators. Flumethasone pivalate is available in various forms, including creams, ointments, and injections.
Method of Synthesis or Extraction Flumethasone pivalate is synthesized by the reaction of flumethasone with pivalic acid. The reaction is carried out in the presence of a catalyst and a solvent. The efficiency and yield of the synthesis process depend on the reaction conditions, such as temperature, pressure, and reaction time. The yield of the synthesis process is typically high, ranging from 80% to 90%. However, the synthesis process requires the use of hazardous chemicals and solvents, which can have adverse environmental and safety considerations.
Chemical Structure and Biological Activity Flumethasone pivalate has a chemical formula of C27H37FO6 and a molecular weight of 476.58 g/mol. It has a similar chemical structure to other glucocorticoids, such as prednisolone and dexamethasone. Flumethasone pivalate works by binding to glucocorticoid receptors and inhibiting the production of inflammatory mediators, such as prostaglandins and leukotrienes. It also has immunosuppressive and anti-proliferative effects.
Biological Effects Flumethasone pivalate has various biological effects on cell function and signal transduction. It can inhibit the production of cytokines, chemokines, and growth factors, which are involved in the inflammatory response. It can also modulate the activity of transcription factors, such as NF-κB and AP-1, which are involved in the regulation of gene expression. Flumethasone pivalate has potential therapeutic and toxic effects, depending on the dose and duration of treatment. It can be used to treat various inflammatory and allergic conditions, such as asthma, eczema, and rheumatoid arthritis. However, it can also have adverse effects, such as immunosuppression, osteoporosis, and diabetes.
Applications Flumethasone pivalate has various applications in medical research, environmental research, and industrial research. In medical research, it plays a crucial role in drug development and clinical trials. It has been used in various clinical trials to evaluate its efficacy and safety in the treatment of various inflammatory and allergic conditions. The findings of these trials have shown that flumethasone pivalate is an effective and safe treatment option for these conditions. However, it can also have potential side effects, such as skin atrophy and adrenal suppression.
In environmental research, flumethasone pivalate has been studied for its effects on ecosystems and its role in pollution management. It can have adverse effects on aquatic organisms, such as fish and amphibians, by disrupting their endocrine systems. It can also contribute to the pollution of water bodies, such as rivers and lakes, through the discharge of wastewater from pharmaceutical manufacturing plants. Therefore, it is essential to monitor and regulate the use of flumethasone pivalate in these industries.
In industrial research, flumethasone pivalate is used in various manufacturing processes to improve product quality and efficiency. It is used in the production of various pharmaceutical products, such as creams, ointments, and injections. However, it is essential to consider the health and safety considerations of the workers who handle these chemicals and solvents.
Future Perspectives and Challenges The use and study of flumethasone pivalate face various limitations and challenges. One of the main challenges is the development of resistance to glucocorticoids, which can limit their efficacy in the long term. Therefore, there is a need to develop new and more effective treatments for inflammatory and allergic conditions. Another challenge is the adverse effects of flumethasone pivalate, which can limit its use in certain patient populations. Therefore, it is essential to monitor and regulate the use of flumethasone pivalate to minimize its potential side effects.
Conclusion:
Flumethasone pivalate is a potent anti-inflammatory agent that is used in the treatment of various inflammatory and allergic conditions. It has various biological effects on cell function and signal transduction, and it has potential therapeutic and toxic effects. Flumethasone pivalate has various applications in medical research, environmental research, and industrial research. However, its use and study face various limitations and challenges, which require further research and development.
Melting Point 219°C(baseonly)
Other CAS Number 2002-29-1
Physical Description Solid
Pictograms Health Hazard
Shelf Life >3 years if stored properly
SMILES CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)COC(=O)C(C)(C)C)O)C)O)F)C)F
Solubility Soluble in DMSO
Storage Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Synonyms Flumethasone pivalate; Locacorten; Locorten; Lorinden; NSC 107680; NSC-107680; NSC107680;
Reference 1: Abdel-Aleem EA, Hegazy MA, Sayed NW, Abdelkawy M, Abdelfatah RM. Novel spectrophotometric determination of flumethasone pivalate and clioquinol in their binary mixture and pharmaceutical formulation. Spectrochim Acta A Mol Biomol Spectrosc. 2015 Feb 5;136 Pt B:707-13. doi: 10.1016/j.saa.2014.09.085. Epub 2014 Sep 30. PubMed PMID: 25448970. 2: Hojyo T. Combination dermatological products: a comparison of betamethasone dipropionate/clotrimazole/gentamicin sulphate and flumethasone pivalate/clioquinol creams. J Int Med Res. 1987 Sep-Oct;15(5):255-63. PubMed PMID: 2960577. 3: Scaglione F, Falchi M, Bichisao E, Fraschini F. Flumethasone pivalate (Locorten) in the treatment of oral diseases. Drugs Exp Clin Res. 1985;11(8):523-6. PubMed PMID: 3915470. 4: Wienert V, Blazek V. [Effect of salicylic acid on the blanching effect of flumethasone pivalate (author's transl)]. Arch Dermatol Res. 1981;271(1):19-27. German. PubMed PMID: 7294880. 5: Mosca M, Zambruno G, Giannetti A. [Double-blind comparison of a betamethasone dipropionate-iodochloroxyquinoline combination and a flumethasone pivalate-iodochloroxyquinoline combination in the therapy of steroid-sensitive dermatoses with superinfection]. G Ital Dermatol Venereol. 1986 Jan-Feb;121(1):XI-XIV. Italian. PubMed PMID: 2939023. 6: Grater WC, Grover FW. Evolution of a topical corticosteroid (flumethasone pivalate) in allergic dermatoses. South Med J. 1967 Nov;60(11):1153-8. PubMed PMID: 4228807. 7: Horsch W, Zerbe A. [Release of flumethasone pivalate from oleogel and W/O emulsion bases in vitro]. Pharmazie. 1982 Nov;37(11):807-8. German. PubMed PMID: 7163369. 8: JAENNER M. [FLUMETHASONE PIVALATE. AN EXPERIENCE REPORT ON A NEW TOPICAL CORTICOSTEROID]. Med Welt. 1965 Apr 24;17:943-7. German. PubMed PMID: 14293915. 9: Ruiz EM, Alaniz JB, Alvarez EG. [Bouble-blind unilateral comparison of difluocortolone valerate and flumethasone pivalate ointments]. Z Hautkr. 1976;51 Suppl 1:51-5. German. PubMed PMID: 795190. 10: CAMBIAGHI G, TOMASINI C. [A NEW ANTIINFLAMMATORY CORTICOSTEROID FOR LOCAL USE: FLUMETHASONE PIVALATE]. Rass Dermatol Sifilogr. 1964 Sep-Oct;17:272-81. Italian. PubMed PMID: 14253770. 11: Ormea F, Muscardin L. [On the topical activity of flumethasone pivalate in pediatric dermatology]. Minerva Dermatol. 1967 Dec;42(12):624. Italian. PubMed PMID: 5622839. 12: Lodge BA, Vincent A. Analysis of flumethasone pivalate formulations by high-performance liquid chromatography. J Chromatogr. 1984 Oct 5;301(2):477-80. PubMed PMID: 6501501. 13: Mulay DN, Sood BK. Clinical Evaluation of Flumethasone Pivalate (locacorten) with Neomycin As a Topical Corticosteroid. Indian J Dermatol Venereol. 1972 Mar-Apr;38(2):89-92. PubMed PMID: 29144364. 14: Blum G, Brand PH. [Scope of indication and therapeutic value of combined forms of use of flumethasone pivalate and the antimicrobial agent vioform]. Ther Umsch. 1966 Aug;23(8):318-22. German. PubMed PMID: 4224259. 15: Flumethasone pivalate (Locorten). Anti-inflammatory, antipruritic. Clin Pharmacol Ther. 1970 Nov-Dec;11(6):927-9. PubMed PMID: 5481576. 16: Kantner A, Horvath F, Prokop V. [Experience with flumethasone pivalate in the treatment of nonseasonal allergic rhinitis]. Z Allgemeinmed. 1971 Dec 20;47(35):1864-5. German. PubMed PMID: 5137912. 17: Mello Mdo C. [Use of flumethasone pivalate with iodochlorxyquinoleine in the treatment of cervicitis]. Hospital (Rio J). 1966 Sep;70(3):745-7. Portuguese. PubMed PMID: 4230326. 18: Wittels W, Gmeinder A. [Clinical experiences with topical applications of flumethasone pivalate (Locacorten)]. Wien Med Wochenschr. 1966 Oct 15;116(42):918-20. German. PubMed PMID: 5953991. 19: Ruiz Moreno F. [Flumethasone pivalate in the field of proctology]. Prensa Med Mex. 1967 Jan-Feb;32(1):61-5. Spanish. PubMed PMID: 5633914. 20: Dugois P, Amblard P. [Clinical trial of a new dermocorticoid: flumethasone pivalate]. Rev Lyon Med. 1968 May 30;17(10):473-5. French. PubMed PMID: 5677093.
PubChem Compound Flumethasone pivalate
Last Modified May 30 2023